Advanced ovarian cancer patients who have had at least 1 chemotherapy treatment are needed for a research study.

UVA Tracking #
HSR200269
Principal Investigator
Linda R Duska
Contact
Rachel Lacy
Contact Email
Contact Phone
434.243.0126
Official Trial Title
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of ther
Study Description

University of Virginia Health System, Division of Gynecologic Oncology is conducting a clinical research study. We want to learn more about how the combination of two experimental drugs affects patients with advanced ovarian cancer. You may be eligible if you have advanced ovarian cancer that has come back, or has stopped responding to your current treatment.

Participation involves a 1-4-week Screening Period, 28-day Treatment Cycles, a treatment period for as long as you benefit from study treatment, an End of Treatment Visit, and a Long-term Follow-up Period. During Treatment, you will need to come on site weekly for the first Cycle, and then biweekly for the following Cycles for about 4 hours each visit. One experimental drug will be administered by IV biweekly and another drug will be taken orally twice a day.

Additional information can be found here: ¬link to clinicaltrials.gov page.

Compensation

Compensation: $50 per visit. Reimbursement: Up to $175 for hotel stay.